EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis. Zhang Y, Lin Y, Cai H, Zhou T, et al. BMC Cancer 2025;25:1638.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhang Y, Lin Y, Cai H, Zhou T, et al. EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis. BMC Cancer 2025;25:1638.
PMID: 41136937